When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.
COTA leverages our proprietary abstraction technology and oncology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.
We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.
Market of current oncologics and decisions to drive future therapeutic areas.
Drug development and build real-world comparator arms.
New ways of thinking about how trials are designed.
COTA captures clinical data from EHR from multiple provider sources across the United States, including both academic and community cancer programs. We also use non-EHR sources such as publicly available and proprietary databases, to generate a rich and precise dataset for use by life sciences companies.
COTA collects all clinically-relevant data points to create a rich, in-depth longitudinal cancer patient journey from our healthcare providers’ EHR. Data elements captured may vary per cancer type, but generally, our data contains (but is not limited to) detailed demographic, pathologic, genomic, treatment, and outcomes data.
We work with life science companies interested in using oncology RWD to accelerate drug development and bring clarity to cancer. We work with the top global pharmaceutical companies, though our partners range from multinational pharma to emerging biotechs.
Interested in learning more about how we can transform cancer care together?